Behind The Mystery - Rare and Genetic Diseases Television Special Looking for Participants
Rare diseases get the spotlight on “Behind The Mystery – Rare and Genetic Diseases;” special episodes of The Balancing Act, which airs on Lifetime weekday mornings at 7AM.
The mission of “Behind the Mystery: Rare and Genetic Diseases” is to educate the public about rare and genetic diseases and treatments, and provide support through collaborations in education with pharmaceutical companies, foundations and patient advocacy groups. Partnering with the Global Genes Project, The Balancing Act is the only television show with a special of this kind, working to bring awareness to the plight of rare disease sufferers and the quest for FDA approved treatments and therapies.
The Balancing Act is currently looking for: people from pharmaceutical companies doing research, or working on drug therapies for any of the many rare diseases out there; advocates or representatives from various rare disease group; people who are part of the rare disease world to continue with the series and its mission to be a place when people in the rare disease community can gather for more information.
The special airs every few weeks, past specials are available for viewing here: http://www.thebalancingact.com/rare/
If you’d like to get involved, please contact:
Carri Levy
Senior Associate Producer
The Balancing Act
[email protected]
Related Links:
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
